The SECURE-AD Patient survey is designed to help understand how the coronavirus pandemic (COVID-19) affects people with atopic dermatitis (also called atopic eczema). They are encouraging all people with atopic dermatitis around the world to participate and report their experience with COVID-19 infection using this survey.

The survey is for people with atopic dermatitis who have been diagnosed with COVID-19 or think they have had COVID-19 infection. It is however important that your COVID-19 symptoms started at least two weeks ago, so you can share your personal experience with your COVID-19 infection.

Filling in the survey will take about 10 minutes and consists of questions about yourself, your atopic dermatitis treatment, other conditions/medications and how the COVID-19 infection affected you.

This survey is anonymous and no identifiable information about you will be stored. If you live in the United Kingdom, you can provide optional permission for us to link your anonymous survey responses to your NHS and public health records, securely through the Guy’s and St Thomas’ Hospital encrypted servers. If you prefer not to provide this information, your survey will remain completely anonymous.

For more information, see the SECURE-AD Patient survey FAQs page and privacy page.

If you’re a clinician, SECURE-AD allows you to report cases of COVID-19 in your AD patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). You can report cases here.